newsfilter
← Latest News
GlobeNewswire·

Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology

Series of preclinical studies demonstrate the therapeutic potential of CY6463, a first-in-class, CNS-penetrant sGC stimulator Oral, once-daily CY6463 is being developed for neurological diseases associated with cognitive impairment CAMBRIDGE, Mass.